Critical Overview of the Risk Scoring Systems to Predict Non-Responsiveness to Intravenous Immunoglobulin in Kawasaki Syndrome by D. Rigante et al.
 International Journal of 
Molecular Sciences
Review
Critical Overview of the Risk Scoring Systems to
Predict Non-Responsiveness to Intravenous
Immunoglobulin in Kawasaki Syndrome
Donato Rigante 1,*, Laura Andreozzi 1, Michele Fastiggi 1, Benedetta Bracci 1,
Marco Francesco Natale 1 and Susanna Esposito 2
1 Institute of Pediatrics, Università Cattolica Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli,
Rome 00168, Italy; laurandreozzi@gmail.com (L.A.); micstiggi@gmail.com (M.F.);
benedetta.bracci@gmail.com (B.B.); mark000@hotmail.it (M.F.N.)
2 Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation,
Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Milan 20122, Italy; susanna.esposito@unimi.it
* Correspondence: drigante@gmail.com; Tel.: +39-06-3015-4290; Fax: +39-06-338-3211
Academic Editor: Kathleen Gilbert
Received: 13 January 2016; Accepted: 15 February 2016; Published: 24 February 2016
Abstract: Kawasaki syndrome (KS) is the most relevant cause of heart disease in children living in
developed countries. Intravenous immunoglobulin (IVIG) has a preventive function in the formation
of coronary artery abnormalities and a poor strictly-curative action in established coronary damage.
More than two decades ago, the Harada score was set to assess which children with KS should be
subject to administration of IVIG, evaluating retrospectively a large cohort of patients with regard
to age, sex and laboratory data. Nowadays, high dose IVIG is administered to all children with a
confirmed diagnosis of KS, but a tool for predicting non-responsiveness to the initial infusion of IVIG
has not been found. The prediction of IVIG resistance is a crucial issue, as recognising these high-risk
patients should consent the administration of an intensified initial treatment in combination with
IVIG in order to prevent coronary injuries. Few reports have focused on factors, referring to both
clinical parameters and laboratory data at the onset of KS, in order to predict which patients might be
IVIG non-responsive. We have analysed three different risk scores which were formulated to predict
IVIG resistance in Japanese children with typical KS, but their application in non-Japanese patients or
in those with incomplete and atypical patterns of the disease has been studied in a fragmentary way.
Overall, our analysis showed that early and definite ascertainment of likely IVIG non-responders who
require additional therapies reducing the development of coronary artery involvement in children
with KS is still a challenge.
Keywords: Kawasaki syndrome; intravenous immunoglobulin; coronary artery abnormalities
1. Introduction
Almost half a century has passed since Kawasaki syndrome (KS) was first reported by Tomisaku
Kawasaki as an enigmatic disease affecting children, and, today, KS still remains uncannily dangerous
due to the intrinsic risk of damaging the vascular system, mostly the coronary arteries, in 25% of
untreated patients. It is no coincidence that KS stands as the most relevant cause of heart disease
in children of developed countries, not only in Japan where the disease is largely observed and
recognized [1,2]. Many shortcomings still exist in studies aimed at defining the etiology of KS, which
makes it an arduous task to improve the recommendations given in KS treatment [3,4]. Though a
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host of clinicians around the world have invested huge effort to unveil the mysteries of KS, studies
related to the delineation of its outcomes remain lacking. The most dangerous manifestations of KS
are not part of the diagnostic criteria, and include myocarditis, congestive heart failure and coronary
artery aneurysms. Prompt treatment with intravenous immunoglobulin (IVIG) has been shown to
resolve all manifestations of KS and to significantly decrease the risk of development of coronary artery
abnormalities (CAA) [5]. Actual therapeutic management, which is centred on the administration
of IVIG within 10 days of the onset of fever, has been categorised according to severity of CAA and
the type of subsequent cardiovascular risk [6]. Indeed, if a patient responds to IVIG, there is a better
chance to decrease the risk of KS-induced cardiovascular complications from 20% to as low as 5% [7].
Many recent data suggest that treatment and prognostic issues are dissociated with the etiology of
KS, though the extent of acute phase response and a younger age at onset are probably related to
patients’ responsiveness to IVIG [8]. The main aim of this review was to analyse the three more recent
risk scores which were formulated to predict IVIG resistance in Japanese populations of children with
typical KS, and to evaluate their pertinence in non-Japanese patients or in those with incomplete and
atypical patterns of the disease.
2. The Harada Score in Kawasaki Syndrome
Methods to predict which children are at greatest risk of developing CAA have been extensively
sought to determine the general prognosis of KS. The first scoring model was formulated in 1991 by
Harada, but it was not intentionally created to assess a general risk of cardiovascular involvement:
it merely tried to identify KS children at higher risk for potential complications, as different issues
related to cost and availability of IVIG made it problematic at that time to treat all children with KS in
Japan. The “Harada score” was developed by retrospectively correlating routine laboratory and clinical
findings in the early stages of KS, i.e., within nine days of onset, with the eventual development of CAA.
The study was set in two parts: the first part aimed to evaluate doses and types of IVIG, the second
aimed to assess the elective indications of IVIG for children with KS. In particular, Harada analysed
data from 865 naïve patients who had not been treated with IVIG, corticosteroids or nonsteroidal
anti-inflammatory drugs, and the scoring criteria included seven items: white blood cell and platelet
counts, C-reactive protein (CRP), hematocrit, albumin, age at diagnosis, and male sex. Children with
KS who satisfied at least four of these seven criteria were thought to be candidates for IVIG treatment
(List 1) [9].
List 1. The Harada score (1991) was extrapolated by a multicentre study carried out to evaluate
the effectiveness of different doses and kinds of intravenous globulin (IVIG) in 865 naïve patients with
Kawasaki syndrome, analysed retrospectively with regard to laboratory data, age, and sex: the score
was an attempt to establish a set of criteria for starting treatment with IVIG.
The Presence of at Least 4 of these 7 Criteria prompted the Administration of Intravenous
Immunoglobulin to the Child with Kawasaki Syndrome:
‚ White blood cell count > 12 ˆ 103/mm3
‚ Platelet count < 35 ˆ 104/mm3
‚ C-reactive protein > 3+
‚ Hematocrit < 35%
‚ Albumin < 3.5 g/dL
‚ Age < 12 months
‚ Sex Male
Although this score should not be used to triage children who do not need IVIG, its influence
was dispelled over time because, nowadays, IVIG is necessarily given to “all” KS patients. In 2014
Tewelde et al. [10] performed a retrospective chart review of 105 patients admitted to the Cleveland
Children’s Clinic from 2001 to 2011 whose final diagnosis was KS, and suggested that the Harada
score was effective also in the USA population (having a median age at time of diagnosis of 2.8 years),
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with the aim of selecting high-risk children who might benefit from further evaluation and additional
therapies beyond standard IVIG. They also concluded that the score had adequate sensitivity (90%) in
the selection of children with higher risk of developing CAA, though low specificity (51%).
3. The Risk Scores for the Evaluation of Non-Responsiveness to Intravenous Immunoglobulin in
Kawasaki Syndrome
Different researchers have focused on better recognising early predictors of IVIG resistance with
the hope of developing risk scoring algorithms and estimating the probability of a successful response
to IVIG. In 2009, Son et al. [11] indicated that a percentage of KS patients varying from 13% to 21%
were resistant to IVIG, displaying persistent or recrudescent fever after first IVIG administration.
Few scoring models to predict the risk of CAA have been formulated. The first of these, reported by
Asai in 1983, tried to determine an indication for cardiac catheterization during a period in which
echocardiography was not routinely used in Japan in the management of KS [12].
Another scoring model was created by Nakano et al. [13] in 1986, starting from clinical and early
laboratory findings from 78 children who were hospitalized since the 4th day of fever to the 7th: they
found that age at onset, CRP, and baseline platelet count were useful items in the differentiation of
patients at higher risk of CAA.
In 1998, Beiser et al. [14] constructed a sequential risk classification tool from a cohort of 212
children with KS treated with IVIG during the first 10 days of disease to predict which patients
might develop CAA, and evaluate baseline hemoglobin level, neutrophil count, platelet count, and
body temperature on the day in which IVIG was infused: the authors distinguished low-risk and
high-risk children, among whom extensive cardiac monitoring and even additional therapies could
be appropriate.
In 2000, after a multivariate analysis of 82 KS patients, Fukunishi et al. [15] noted that those with
CRP above 100 mg/L, lactate dehydrogenase above 590 IU/L and/or hemoglobin below 10 g/dL
before initial treatment with high-dose IVIG were probably IVIG non-responders; they also noted that
baseline total bilirubin was significantly higher in IVIG non-responsive patients by univariate analysis.
The prediction of IVIG resistance has been also evaluated by three more recent risk scores,
formulated in the last decade and based on children with typical KS: these three scoring systems have
been considered and schematized in Table 1 for this review.
Table 1. The latest scoring systems evaluating non-responsiveness to treatment with intravenous
immunoglobulin in children with Kawasaki syndrome: the Egami and Kobayashi scores were primed
in 2006, the Sano score in 2007.
Egami Risk Score [16]
A cut-off point ě3 identifies patients with Kawasaki syndrome at high risk of being resistant to intravenous immunoglobulin
Points
Age <6 months 1 point
Days of illness <4 1 point
Platelet count <300 ˆ 109/L 1 point
C-reactive protein >8 mg/dL 1 point
Alanine aminotransferase >80 IU/L 2 points
Kobayashi Risk Score [17]
A cut-off point ě4 identifies patients with Kawasaki syndrome at high risk of being resistant to intravenous immunoglobulin
Points
Sodium ď133 mmol/L 2 points
Days of illness at initial treatment ď4 2 points
Aspartate aminotransferase ě100 IU/L 2 points
Percentage of neutrophils ě80% 2 points
C-reactive protein ě10 mg/dL 1 point
Age ď12 months 1 point
Platelet count ď300 ˆ 109/L 1 point
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Table 1. Cont.
Sano Risk Score [18]
Non-responsiveness to intravenous immunoglobulin is predicted by the presence of at least 2 of 3 predictors in the child
with Kawasaki syndrome
C-reactive protein ě7.0 mg/dL
Total bilirubin ě0.9 mg/dL
Aspartate aminotransferase ě200 IU/L
3.1. The Egami Score
In 2006, Egami et al. [16] defined a prediction score of non-responsiveness to IVIG evaluating
through logistic regression analysis the clinical, laboratory and demographic data of 320 Japanese
patients, hospitalized in the period 1998–2004, who received IVIG (2 g/kg as a single infusion) by the
9th day of disease, without cardiovascular complications at initial treatment: the number of patients
with resistance to IVIG was 41 (13%), while the other 279 patients were full responders. In this model
(in which the authors assigned 1 point for age, duration of illness in days, platelet count, CRP and 2
points for serum alanine aminotransferase, and in which a cut-off point ě3 pinpointed patients with
KS at high risk of being resistant to IVIG), the clinician should recognize the IVIG non-responders
with 78% sensitivity and 76% specificity, and predict the potential development of CAA with 61%
sensitivity and 81% specificity.
However, in the same year, Tremoulet et al. [19] (at the University of California, San Diego)
evaluated the Egami score in 362 children diagnosed with KS and found that more than 60% of
IVIG-resistant patients had been missed.
3.2. The Kobayashi Score
Also in 2006, Kobayashi et al. [17] created a new model to predict non-responsiveness to IVIG in
children with KS, reviewing retrospectively the clinical records of 546 KS patients hospitalized in the
period 2000–2004 in 13 Japanese hospitals; a further group of 204 patients hospitalized in the period
2004–2006 was also studied prospectively to confirm accuracy of the previous results. IVIG was given
as 1 g/kg per day for 2 days in combination with aspirin (30 mg/kg, then reduced to an anti-platelet
dosage after that CRP was normalized) and dipyridamole (2 mg/kg per day). Patients were considered
to be non-responders if they were persistently febrile or if they returned with KS symptoms after
defervescence. Univariate analysis found 10 laboratory variables (percentage of neutrophils, platelet
count, total bilirubin, aspartate and alanine aminotransferases, sodium and chloride, proteins and
albumin, and CRP) as likely predictors of IVIG non-responsiveness, in combination with three
demographic variables (male sex, age expressed in months, and the number of days of illness until
when treatment was started), which were all included in the stepwise forward logistic regression
analysis. A risk score was finally developed by the integration of laboratory variables (evaluated before
treatment) and demographic data: this model was used to define two risk levels for patients with
KS, indicating low- and high-risk of non-responsiveness to IVIG. In particular, they found that a high
level of aspartate aminotransferase, CRP, percentage of neutrophils, and also low age in months, low
serum sodium and low platelet count, combined with early infusion of IVIG, were all independent risk
factors for IVIG non-responsiveness. Sensitivity and specificity in revealing IVIG non-responders were
86% and 67%, respectively, in the logistic model. In the high-risk group (with score >4), the occurrence
of IVIG non-responsiveness was 43%, but it was only 5% in the low-risk group (with score <3). The
occurrence of CAA was 16% and 1%, respectively, in the high- and low-risk groups. Because KS
patients displaying higher scores were at higher risk for the development of CAA, a careful follow-up
should be warranted in such patients and a more aggressive initial anti-inflammatory treatment or
alternative treatments considered.
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3.3. The Sano Score
In 2007, Sano et al. [18] analysed retrospectively clinical, laboratory, and echocardiographic data
of 112 patients with KS aged 1 month to 7 years, hospitalized between 1999 and 2000, to evaluate three
potential predictors of non-responsiveness to IVIG: CRP, total bilirubin, and aspartate aminotransferase.
This retrospective study was intended to elucidate the correlation between the response to IVIG
given within 2 days (1 g/kg/day for two days) and clinical parameters at the onset of KS; the final
purpose of the study was to ascertain which children would be non-responsive to the first course
of IVIG, for whom alternative intensive primary treatment should be considered. In particular, KS
patients displaying the increase of at least two of three predictors at the onset of disease, before IVIG
administration, were considered likely non-responders to IVIG; the sensitivity and the specificity of the
score were 77% and 86%, respectively. The total incidence of CAA was extremely high (71%) in IVIG
non-responsive patients compared to IVIG responders (5%), confirming the potential prediction of CAA
at the onset of the disease (earlier than IVIG infusion) by the use of simple biochemical laboratory data.
Sano et al.’s [18] analysis led to similar results to those obtained in the study by Fukunishi et al. [15],
who also evaluated the possibility of non-responsiveness to IVIG at disease onset in a cohort of 82 KS
patients assessed consecutively in a single Japanese hospital in 2000, choosing body temperature on the
6th day after IVIG administration as an endpoint, instead of CAA: 13 out of 82 patients remained febrile
on day 6 after IVIG, and all were characterised by significantly higher values of CRP (>100 mg/L),
total bilirubin, lactate dehydrogenase, γ-glutamyl-transpeptidase, and lower values of haemoglobin
(<11 g/dL) before treatment.
4. A Critical Assessment of the Risk Scoring Systems for Kawasaki Syndrome
All these above-mentioned scores have considered multiple items, which have been listed
synthetically in Table 2. High CRP level was globally considered a risk factor for non-responsiveness
to IVIG and the subsequent risk of CAA in all systems, probably as a result of stronger systemic
inflammation driving endothelial abnormalities and final development of cardiovascular complications.
In addition, most scores have considered thrombocytopenia and patient’s age less than 6–12 months as
individual risk factors for the occurrence of CAA.
Table 2. Items evaluated in the different risk scores for Kawasaki syndrome.
Items Egami Score [16] Kobayashi Score [17] Sano Score [18]
C-reactive protein   
Age  
Days of illness  
Alanine aminotransferase 
Total bilirubin 
Aspartate aminotransferase  
Sodium 
Percentage of neutrophils 
Platelet count  
These risk scores, characterised by different sensitivity and specificity, should be judged and
scrutinized in light of the different clinical studies in which they were formulated (see Table 3).
First of all, we need to recognise that scores were based on data deriving from Japanese children,
and we are all aware that variations in KS incidence or severity of presentation in different populations
probably reflect genetic and environmental differences, which makes it problematic to indiscriminately
apply these scores to non-Japanese populations. Another relevant issue is the sample size used in
each study: Kobayashi and Egami included 750 and 321 patients, respectively [16,17], while Sano
considered only 112 patients, with obvious limitations in the study itself [18]. Furthermore, diagnosis
of KS was based on different clinical criteria, and only Sano et al. [20] assessed CAA adjusting the
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dimensions of coronary arteries to the patient’s body surface area (by linear regression analysis
after comparison with healthy controls). In addition, each study used a different regimen of IVIG
dosage. A single IVIG dose of 2 g/kg (the actual standard therapy for KS in Europe, USA, United
Kingdom, Australia, and many regions of Asia [21]) was used by Egami et al. [17] in combination with
daily aspirin (30 mg/kg/day) [16]. Kobayashi et al. [17] used 1 g/kg/day of IVIG for two days in
combination with aspirin and dipyridamole. Conversely, Sano et al. [18] used two separate infusions
of IVIG on two consecutive days (at a daily dose of 1 g/kg/day) in the first two days since disease
onset in combination with aspirin: in this case, timing of IVIG administration could be an important
limitation of the study, as a very early treatment of KS within four days represents an additional
risk factor for IVIG non-responsiveness [22]. Indeed, also Egami and Kobayashi demonstrated that
untimely administration of IVIG in the first four days of illness might be a further factor contributing
to non-responsiveness [16,17].
Table 3. Differences among the clinical studies for which the latest risk scores for Kawasaki syndrome
were formulated.
Clinical Studies Egami Score [16] Kobayashi Score [17] Sano Score [18]
Year of publication 2006 2006 2007
Population Japanese Japanese Japanese
Sample size 320 patients 750 patients 112 patients
Diagnosis of Kawasaki
syndrome Japanese criteria
Revision of the Japanese
criteria (5th edition) Criteria not specified
Diagnosis of coronary artery
abnormalities
Not adjusted for body
surface area
Not adjusted for body
surface area
Adjusted for body surface
area (according to de Zorzi’s
criteria)
Treatment with intravenous
immunoglobulin (IVIG)
Single 2 g/kg/dose within 9
days of illness
1 g/kg per day for 2
consecutive days
1 g/kg per day (within 2
days of illness) for 2
consecutive days
Definition of
non-responsiveness to
intravenous
immunoglobulin (IVIG)
Persistent fever (ě37.5 ˝C)
and fall in C-reactive protein
by less than 50% within 48 h
after IVIG treatment
Persistent fever (ě37.5˝C)
lasting more than 24 h or
recrudescent fever (after an
afebrile period) associated
with disease symptoms
Persistent fever (ě37.5 ˝C)
over 24 h after finishing
IVIG infusion
Sensitivity 78% **61% * 86% ** 77% **
Specificity 76% **81% * 67% ** 86% **
* Referring to the identification of children at higher risk to develop coronary artery abnormalities; **
Referring to the identification of children at higher risk to be non-responders to the administration of
intravenous immunoglobulin.
The last difference among the three studies was the definition of IVIG non-responders: it is known
that up to 20% of KS patients might present a persistent or recrudescent fever after IVIG, remaining
at high risk of developing CAA [23–25]. Egami defined “responder” as a patient in whom fever
disappeared and CRP dropped by more than 50% within 48 h after IVIG [16]. Kobayashi defined
“non-responder” as a patient who had persistent fever (ě37.5 ˝C) or a recrudescent fever after an
apparent initial defervescence [17]. Finally, Sano defined non-responsiveness to IVIG as persistent
fever (ě37.5 ˝C over 24 h) after completing IVIG infusion [18]. The variable performance of these three
scores in the prediction of IVIG resistance in children with KS might be also attributed to all these
differences collectively.
In 2011, Sleeper et al. [26] performed a randomised trial with pulsed corticosteroids for treatment
of KS to assess the properties of the three risk scores primed in Japan, examining whether corticosteroid
therapy reduces the risk of CAA in a North American population of KS patients classified as IVIG
resistant; the authors found a low sensitivity (42%, 33%, and 40% for the Egami, Kobayashi, and Sano
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scores, respectively), but a moderate-to-high specificity (85%, 87%, and 85%, respectively). These
results suggested that the use of Japanese-based scores in North American children of mixed ethnicity
might leave out patients with higher risk who could be ideal candidates for additional therapies to
interrupt the disease process.
Until 2015, the benefit of different risk scores to predict IVIG resistance had not been verified
in children with an incomplete pattern of KS, which is more prevalent in both infants and older
children, for whom the duration of fever is probably longer than in typical KS. In 2015, however,
Kanamitzu et al. [27] evaluated the performance of Egami, Kobayashi and Sano scores in 51 patients
with incomplete KS, reviewing retrospectively the clinical records of those who received IVIG in
the period 2005–2012. This study showed that children with incomplete KS were not significantly
different between IVIG-resistant and responders according to the Egami, Kobayashi and Sano scores.
Conversely, a significant difference was noted for children with a typical KS: in particular, Egami and
Kobayashi’s risk scores worked better in the cases of typical KS, while Sano’s score worked better in
incomplete KS cases.
One possible reason is that this score did not consider patients’ ages and the overall number of
febrile days as risk factors. Another potential reason is that the Sano score includes total bilirubin,
suggesting a severe diffuse systemic inflammation just in patients with incomplete KS [27].
5. Future Directions in the Evaluation of Children with Kawasaki Syndrome
The relationship between newly recognized laboratory markers and failure to respond to
the conventional treatment with IVIG in KS is puzzling. For instance, Huang et al. [28] found
that serum haptoglobin/apolipoprotein A-I ratio was significantly higher in a cohort of 64 KS
patients, and suggested that this ratio could be a supplemental diagnostic marker for differentiating
KS from other febrile disorders of childhood. In addition, Demir et al. [29] demonstrated that
neutrophil-to-lymphocyte ratio (NLR) values, which can be calculated by dividing the neutrophil
count by the lymphocyte count, were significantly higher in 75 patients with KS complicated by CAA
than in the ones without. In particular, Ha et al. [30] evaluated the NLR in 587 patients with KS before
IVIG, two days after IVIG (regardless of defervescence), and three to four weeks after defervescence:
children who were resistant to IVIG had higher NLRs, and multivariate analysis showed that the NLR
calculated two days after IVIG predicted both development of CAA and resistance to IVIG.
Sato et al. [31] determined retrospectively the predictors of IVIG resistance in a cohort of 129
children diagnosed with KS in a single-centre: the IVIG-resistant group (consisting of 21 patients)
had significantly increased serum levels of interleukin (IL)-6 (207.7 ˘ 127.1 versus 102.7 ˘ 97.4 pg/mL
for IVIG responders). The authors concluded that resistance to IVIG therapy might be heralded by
elevated levels of IL-6, and that IVIG-resistance should contemplate IL-6 in the scoring system.
The contribution of genetics to KS susceptibility and even to responsiveness to IVIG is a matter of
great debate. It has been reported that siblings of KS patients have a 6 to 10-fold greater incidence of
the disease than the general population [32]. In addition, it has been calculated that the heritability of
KS, i.e. the ratio of siblings to population incidence of KS, is only slightly lower than that of type 1
diabetes and about four times higher than that of allergic asthma [33]. These and many other findings
strongly suggest that genetic factors have a role to play in the occurrence of KS, and in conditioning its
severity: studies on genetic characteristics of patients with KS have not, for the time being, precisely
identified which kind of genetic markers favour or protect humans from the development of KS.
Furthermore, other genetic systems have been associated with resistance to IVIG and development of
CAA, including the gene coding for caspase-3, the gene associated with the low affinity receptor of
the Fc region of γ-immunoglobulins, and genes related to the transforming growth factor-β signalling
pathway [34,35]. Therefore, the existence of genetic factors affecting patients’ responses to treatment
with IVIG and risk of cardiac complications is providing further clues to better understanding the
overall KS inflammation.
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6. Conclusions
Children suspected to have KS should receive prompt treatment with IVIG (2 g/kg of body weight
as a single dose) within 10 days of illness onset [36]. Many researchers have scrutinised the clinical
data and laboratory parameters at onset predicting the risk of CAA [37,38]. Risk factors for CAA are
duration of fever longer than two weeks, platelet count, increased acute phase reactants, and age less
than five years. No statistically significant difference in the incidence of coronary aneurysms could be
observed in consideration of aspirin dosage [39]. Damage to coronary arteries is still a substantial risk
for a not negligible percentage of children with KS, mostly in the case they show resistance to IVIG [40]:
the identification of this cluster of children at the time of a first clinical assessment might help in
discerning those who would benefit from a combined primary treatment with IVIG and corticosteroids.
Unfortunately, the available risk scoring systems, which were developed after the analysis of data
from Japanese patients, cannot be systematically adopted for patients of different ethnic groups living
in other countries. Therefore, the actual identification of non-Japanese patients at higher risk of IVIG
resistance is still a challenge.
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